27 August 2014: Anteo Diagnostics Limited (ASX: ADO) (“Anteo”),...

27 August 2014: Anteo Diagnostics Limited (ASX: ADO) (“Anteo”), in compliance with its continuous disclosure obligations announces that it has entered into a second agreement with a global healthcare company to investigate additional applications of Anteo’s proprietary surface modification technologies on the Point of Care device that they are developing. The objective of this study is to assess, in a holistic manner, the multiple advantages that Mix&Go and Anteo knowhow can provide across the device.
Depending on the outcome of the study, further commercial negotiations may be undertaken.
Anteo’s Chief Executive Officer, Dr. Geoff Cumming said, “We view this agreement as an important stepping stone. To date our focus has been restricted to one component of the system. This agreement provides us with access to all other surfaces in the system and opens up the possibility of extracting significant additional benefits. We expect that using Mix&Go throughout the system will deliver better outcomes than those possible using conventional approaches.”
“For the first time we will be able to tune the system for our benefit rather than trying to extract benefits from a system that has been tuned for a non-Mix&Go approach. This concession allows us to target a best in class product for our partner. The ongoing feedback we receive from our client continues to be encouraging.
This announcement is testament to the strength of our patented technology and the respect in which our scientific capabilities are held. ”


"Global healthcare company..." Dammit!
Great announcement though.